Baxter International Inc leadership

Hider was appointed President and Chief Executive Officer and a director of Baxter on August 19, 2025, after a robust search process, and is the only non-independent director on the Board. He previously served as Chief Executive Officer of ATS Corporation, a global automation solutions technology company, from 2017 to 2025, and as Chief Executive Officer and President of Taylor Made Group, LLC from 2016 to 2017; earlier he held senior roles at Danaher Corporation, including President of Veeder-Root, and various finance and management positions at General Electric Company, and he serves on the board of Tennant Company.

Shafer is the independent Non-Executive Chair of the Board, appointed in connection with Andrew Hider's August 2025 appointment, and previously served as Baxter's Executive Chair and Interim CEO from February 2025 to August 2025. He is the former Chair and Chief Executive Officer of Cerner Corporation, a leading provider of health information technologies, from 2018 to 2021, earlier held senior leadership roles at Philips Healthcare including CEO of Philips North America as well as roles at Hillrom, GE Medical Systems, Hewlett Packard's Medical Products Group and Johnson & Johnson, and currently serves on the boards of Tactile Systems Technology, Inc. and Veracyte, Inc.

Ampofo is Senior Vice President, Parts & Distribution Services and Supply Chain for Boeing Global Services at the Boeing Company, a role he has held since 2022, and previously chaired Boeing's Supply Chain Operations Council; he earlier held supply chain and procurement leadership roles at United Technologies Corporation. He serves on Baxter's Quality and Regulatory Compliance Committee and will become its chair in May 2026 upon Dr. Stephen Oesterle's retirement.

Craig is the former Chief Executive Officer and President of Meritor, Inc., a global supplier for commercial vehicle manufacturers, where he served as CEO from 2015 to 2021 and earlier as Chief Financial Officer; he spent 15 years at Deloitte & Touche LLP, including five years as an audit partner, and held senior roles at General Motors Acceptance Corporation. At Baxter he chairs the Audit Committee and serves on the Compensation and Human Capital Committee, and he also serves on the boards of Arcosa, Inc. and Hyliion Holdings Corp.

McDonnell is the former Executive Vice President and Chief Financial Officer of Biogen Inc., a global biotechnology company, where he served from 2020 to 2025; he previously served as CFO of IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation and EchoStar Communications Corporation, and spent 14 years at PricewaterhouseCoopers LLP, including four years as a partner. He joined the Baxter Board in February 2026 and serves on the Audit Committee, and he also serves on the board of Merit Medical Systems, Inc., where he chairs the Audit Committee.

Morrison is the former Executive Vice President, Customer Support Services and Chief Information Officer of Cardinal Health, Inc., where she served from 2009 to 2018; she previously served as CIO of both Motorola, Inc. and Office Depot, Inc., as CEO of Mainstay Partners, and held senior IT positions at General Electric Company, PepsiCo, Inc., The Procter & Gamble Company and The Quaker Oats Company. At Baxter she chairs the Nominating, Corporate Governance and Public Policy Committee and serves on the Audit Committee, and she also serves on the board of Amerant Bancorp Inc.

Schlichting is the former President and Chief Executive Officer of Henry Ford Health System, a non-profit healthcare organization she led from 2003 to 2017; earlier she served as President of the Eastern Region of Catholic Health Initiatives, President and CEO of Riverside Methodist Hospitals, and Executive Vice President and COO of Akron City Hospital and Summa Health System. At Baxter she chairs the Compensation and Human Capital Committee and serves on the Quality and Regulatory Compliance Committee, she previously served as Lead Independent Director during the 2025 interim CEO period, and she also serves on the board of Encompass Health Corporation.

Wendell is the former Senior Vice President of Strategy and Business Development and Licensing at Covidien plc, where she held roles of increasing responsibility from 1986 to 2015, including managing acquisitions, divestitures and licensing. She later served as a senior advisor for the healthcare investment banking practice at Perella Weinberg Partners L.P. and for the strategy and corporate finance practice at McKinsey & Company, and at Baxter she serves on the Compensation and Human Capital Committee and the Quality and Regulatory Compliance Committee while also serving on the boards of Axogen Inc., Hologic, Inc. and Solventum Corporation.

Dr. Wilkes is the former Dean of the University of Virginia School of Medicine, where he now serves as Dean Emeritus, and is the co-founder and Chief Scientific Officer of ImmuneWorks Inc., a biotechnology start-up. At Baxter he serves on the Nominating, Corporate Governance and Public Policy Committee and the Quality and Regulatory Compliance Committee.

Grade served as Baxter's Executive Vice President and Chief Financial Officer and was a named executive officer for 2025. Effective March 16, 2026, he ceased serving as CFO and began serving in an advisory capacity through April 30, 2026.

Zielinski is Baxter's Senior Vice President and Chief Accounting Officer. She began serving as Baxter's Interim Chief Financial Officer as of March 16, 2026, following Joel Grade's departure from the CFO role.

Knight served as Baxter's Executive Vice President, Chief Operating Officer and Interim Group President of Medical Products & Therapies, and was a named executive officer for 2025. Her departure from the company was effective on October 29, 2025.

Rasul served as Baxter's Executive Vice President and Group President of Healthcare Systems & Technologies and was a named executive officer for 2025. Effective April 1, 2026, he will cease serving in that role in connection with his departure from Baxter.

Rosenbloom serves as Baxter's Executive Vice President and General Counsel and was a named executive officer for 2025. For purposes of the 2025 annual incentive plan, his net sales metric was measured on a company-wide basis.

Sonig served as Baxter's Executive Vice President and Group President of Pharmaceuticals and was a named executive officer for 2025. His departure from the company was effective on December 1, 2025.

Soriano serves as Baxter's Group President of Infusion Therapies & Technologies (ITT) and Pharmaceuticals, and was a named executive officer for 2025. She assumed her current role on December 1, 2025.